Open main menu

Psychiatrienet β

Fluvoxamine-mirtazapine

Revision as of 09:57, 8 May 2009 by Alexandra (talk | contribs)
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine
Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine

Switch medication from fluvoxamine to mirtazapine.[1] [2]

Nietinrijdenbord.png Stop fluvoxamine
  • Before day 0: gradually reduce dosage of fluvoxamine to a maximum of 50 mg/ day, when this dosage is > 50 mg/day.
  • Day 1: reduce fluvoxamine to a dosage of 25 mg/day.
  • Day 8: stop administration of fluvoxamine.
Eenrichtingbord.png Start mirtazapine
  • Day 8: start administration of mirtazapine in a low dosage of 15 mg/day for one week.
  • Day 15: increase dosage of mirtazapine to normal (30 mg/day).
Infobord.png More information
  • Caution with this switch is necessary, because fluvoxamine slows the metabolism of mirtazapine via CYP1A2, CYP2C9, CYP2D6 and CYP3A4. The inhibiting effect can continue up to two weeks after stopping fluvoxamine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.